A fixed-dose oral tablet with a 101 mg label claim of alpha ketoanalogue to leucine calcium salt per unit is manufactured as part of a multi-ketoacid and amino acid supplement used under protein-restricted dietary management in chronic kidney disease stages 4–5. The finished tablet contains other calcium ketoacid salts in a fixed ratio: 67 mg alpha ketoanalogue to isoleucine calcium salt, 86 mg alpha ketoanalogue to valine calcium salt, 68 mg alpha ketoanalogue to phenylalanine calcium salt, and 59 mg alpha-hydroxyanalogue to methionine calcium salt, together with lysine, threonine, tryptophan, histidine, and tyrosine. This ratio is not arbitrary; it is structured to provide nitrogen-free carbon skeletons that accept amino nitrogen through transamination while restricting total nitrogen intake. A single tablet supplies approximately 36 mg nitrogen and approximately 50 mg elemental calcium from the combined calcium salts. The exact core weight and quantitative excipient composition are not disclosed in public registration dossiers; the following process controls are drawn from standard pharmaceutical processing of readily soluble calcium ketoacid salts and from the known susceptibility of the free ketoacid to decarboxylation. Direct compression is precluded because the multicomponent dry blend tends to segregate and because the fine crystalline calcium salt has irregular flow under hopper conditions. Wet granulation is therefore used in a high-shear vertical granulator with an aqueous binder phase consisting of povidone K30 at 3–5% w/w of the final granule. The binder solution is metered in until the end point is reached by impeller torque or power consumption; for a 150 L production-scale bowl, the endpoint typically falls within 3–8 kW per 100 kg batch. The wet mass is dried immediately in a fluid-bed dryer with inlet air temperature 60–70°C to a final moisture content of 1.5–2.5% w/w as measured by Karl Fischer method Ph. Eur. 2.5.12. The dried granules are screened through 1.0 mm and 0.5 mm sieves, blended with microcrystalline cellulose PH-102 at 10–15% w/w as a dry binder, crospovidone at 2–5% w/w as disintegrant, and magnesium stearate at 0.25–0.5% w/w. Compression is performed on a 19-station rotary tablet press equipped with 10 mm round concave punches, with precompression force 2–4 kN and main compression force 12–20 kN. Core hardness is maintained at 80–120 N, and friability is controlled at not more than 1.0% by USP 1216. The core is film-coated with an aqueous hydroxypropyl methylcellulose or polyvinyl alcohol dispersion to a weight gain of 2–4% w/w; the coating reduces the bitter, metallic taste of the calcium ketoacid complex and provides a moisture-barrier function. The analytical control strategy includes HPLC assay per Ph. Eur. 2.2.29 with UV detection after derivatisation of the ketoacid moiety; system suitability requires baseline separation of leucine and isoleucine ketoanalogue peaks and a tailing factor not more than 2.0. Dissolution testing is performed with USP 711 Apparatus 2 at 50 rpm in 900 mL of 0.1 M hydrochloric acid. A routine acceptance criterion of Q = 75% at 45 min is used for the immediate-release tablet form. Storage is specified at not more than 25°C and not more than 60% relative humidity; desiccant in HDPE containers is required because the calcium salt is hygroscopic and can undergo hydrolytic degradation at higher water activity.

In hospital pharmacy compounding and commercial capsule formats, the same API is governed by a different set of powder-rheology constraints. A single-entity hard gelatin or hydroxypropyl methylcellulose capsule containing 50–150 mg of alpha ketoanalogue to leucine calcium salt is prepared from a direct-fill powder or from dry granulation. Direct filling is not acceptable when the fine crystalline fraction has a Carr Index above 25% and forms a stable bridge in the powder hopper unless the blend is conditioned with 0.5–1.0% w/w colloidal silicon dioxide and 25–40% w/w microcrystalline cellulose. Dry granulation by roller compaction is preferred over wet granulation to avoid aqueous recrystallization of the soluble calcium salt on granule surfaces. The roller-compacted ribbon is milled at 1.25 mm, and the resulting granules are filled into size 1 capsules using a dosator or tamping-pin machine. Fill weight variation is controlled at not more than 4.0% RSD. Disintegration time is tested at 37±2°C in purified water; the limit is not more than 30 min for hard capsules. Gelatin shells soften above 30°C and require storage below 25°C, while HPMC shells are less moisture-sensitive but develop higher static charge and may require humidification to 45–55% RH before filling. No enteric coating is required because the ketoacid is stable at gastric pH. Terminal product testing includes uniformity of dosage units by USP 905, with acceptance value not more than 15.0. This format is used when the patient requires divided dosing or cannot swallow the multi-API tablet.

How Does High-Dose Multi-Ketoacid Tablet Compression Avoid Capping at 101 mg Strength?

Because the calcium salt is freely soluble, wet granulation can create a recrystallized film on granule surfaces when the drying rate is uncontrolled, and this film behaves as a weak interface under compaction. Precompression force in the range 2–4 kN is used before main compression of 12–20 kN, with punch head flat diameter 10 mm and punch penetration depth 2.5–3.5 mm. The dwell time at production speed 30–60 rpm on a 19-station rotary press is 30–80 ms; below 30 ms the viscoelastic recovery of the granule is incomplete, and above 80 ms the output falls below acceptable line rate. If the moisture content rises above 2.5% w/w, the calcium salt softens and migrates to the granule surface during drying, producing radial edge capping in the tablet core. The use of microcrystalline cellulose PH-102 at 10–15% w/w provides plastic deformation and absorbs residual water, while crospovidone at 2–5% w/w provides disintegration without significantly reducing tensile strength. A two-step screening operation to remove fines below 150 µm before final blending is necessary because the fine fraction of the crystalline calcium salt accumulates in the lower punch cavity, causing weight variation and edge capping. The compression force is monitored continuously, and tablets outside 80–110 N hardness are rejected. Batch-to-batch variance is reduced by using granulation end point by torque rather than fixed time. If the granulation end point is reached before uniform water distribution, recrystallization occurs at the dryer tray surface, and the first 30% of the dried batch shows lower dissolution due to API migration. This scale-up fault is known in fluid-bed and tray drying; therefore granule moisture is sampled at 10-minute intervals during drying, and the process is stopped at 1.8–2.2% w/w. Near-infrared moisture sensors are used in production-scale fluid-bed dryers to stop drying at the target endpoint rather than relying on fixed drying time.

When Granule Sachets Require Aqueous Wet Granulation to Maintain Dose Uniformity

Oral granules for sachet administration are specified when the patient cannot swallow the multi-API tablet or capsule. A single-dose sachet contains 101 mg alpha ketoanalogue to leucine calcium salt together with a non-cariogenic, low-sodium, low-potassium diluent system. Mannitol at 60–75% w/w is preferred over sucrose because of reduced glycaemic load and compatibility with the calcium salt. Wet granulation is performed in a top-spray fluid-bed granulator with a binder solution of hydroxypropyl cellulose at 2–5% w/w in purified water. The inlet air temperature is held at 60–70°C, product temperature at 30–40°C, and spray rate is adjusted to maintain an atomization pressure of 1.5–2.5 bar. The granulation end point is determined by a product moisture set point of 1.5–2.0% w/w after drying; overdrying below 1.0% w/w increases electrostatic charge and causes segregation of the API from the larger mannitol granules. The dried granules are screened through 710 µm and filled into unit-dose sachets at a fill weight of 1.0–2.0 g per sachet. Fill weight variation is controlled at ±5.0% of target. The sachet is heat-sealed with a polyethylene terephthalate / aluminium / polyethylene laminate to provide water vapour transmission less than 0.1 g/m²/day. Re-dispersion in 50 mL of purified water at 25°C should yield a suspension that passes through a 710 µm sieve with not more than 5% residue. The calcium salt dissolves partially, and the remaining granular fraction disintegrates within 60 seconds. Dissolution testing uses USP 711 Apparatus 2 at 50 rpm in 500 mL purified water. Published data for this specific sachet configuration are limited; therefore the acceptance criterion is justified by method transfer from the tablet test rather than by a dedicated compendial monograph.

Parenteral Calcium Salt Solubility and Terminal Sterilisation Constraints

An injectable presentation of alpha ketoanalogue to leucine calcium salt is prepared as a sterile aqueous solution in 10 mL type I glass vials. The API is dissolved in water for injection at a concentration of 10 mg/mL based on the anhydrous salt, and the pH is adjusted to 6.0–7.5 with diluted hydrochloric acid or sodium hydroxide solution. The calcium load is stoichiometrically fixed: 100 mg of the anhydrous calcium salt supplies 13.4 mg of calcium, equivalent to 0.335 mmol Ca²⁺. Any pH adjustment must account for the buffer capacity of the ketoacid; if the pH rises above 7.5, the ketoacid undergoes alkaline hydrolysis to the corresponding alpha-hydroxy acid, with a rate constant that increases sharply at elevated temperature. Terminal steam sterilisation at 121°C for 15 minutes is therefore not the first-choice process; aseptic filtration through a 0.22 µm PVDF membrane followed by filling in a Grade A zone is employed. Pre-sterilised vial stoppers must be tested for extractables because the ketoacid has chelating potential toward trace metal ions. The solution is packaged with a nitrogen overlay to limit oxidative decarboxylation. The injection is incompatible with phosphate-containing parenteral nutrition admixtures because of the precipitation of calcium phosphate; the maximum calcium concentration in total nutrient admixtures is governed by ASPEN guidelines and depends on macronutrient concentrations, pH, and temperature. If combined with phosphate-containing solutions, the volumetric ratio must be separated by a flushing line, and no Y-site administration should be performed without a compatibility study. The terminal product is tested for sterility by Ph. Eur. 2.6.1, bacterial endotoxins by Ph. Eur. 2.6.14, particulate contamination by USP 788, and elemental impurities according to ICH Q3D for the parenteral route.

Electrolyte Load Management Drives Calcium Salt Selection in CKD Multidose Formats

The use of a calcium counterion in the ketoanalogue salt is driven by the need to limit sodium intake in CKD patients, and the trade-off is a fixed calcium contribution that must be counted in total daily calcium intake. The same leucine ketoacid formulated as a sodium salt would introduce a measurable sodium burden, whereas the calcium salt avoids sodium but adds elemental calcium. A 3-tablet daily dose based on the 101 mg label claim supplies approximately 150 mg elemental calcium; this is about 15% of the daily value for calcium and becomes clinically relevant when the patient also receives calcium-based phosphate binders or vitamin D analogues. The selection of salt form also affects manufacturing: the calcium salt is less deliquescent than the sodium salt and is preferred for film-coated oral solids because the sodium salt tends to form a semisolid surface film above 65% RH. The electrolyte profile is part of the batch release specification, and the calcium content is verified by complexometric titration per Ph. Eur. 2.5.11 or atomic absorption spectroscopy. In oral granule and capsule formats, the same stoichiometric calcium load applies, and the dose must be documented on the label so that nephrologists can adjust calcium-based phosphate binder therapy. The elemental impurity control strategy for oral and injectable routes follows ICH Q3D; the parenteral route has a lower cadmium and mercury permitted daily exposure, requiring dedicated raw-material qualification and process equipment compatibility. No additional electrolyte adjustment is made in the tablet core beyond the inherent calcium content of the ketoacid salts because added sodium chloride or potassium chloride would defeat the purpose of the formulation in CKD.